Scan barcode
![Non-CML Myeloproliferative Diseases, an Issue of Hematology/Oncology Clinics of North America, Volume 26-5 by Ross Levine](https://558130.bdp32.group/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEZhdmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f30f021a61a91e3f4a69d99c6d979065bb900798/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFJc0FXa0M5QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--038335c90cf75c275ae4d36968ac417dc4a0a3e3/Non-CML%20Myeloproliferative%20Diseases,%20an%20Issue%20of%20Hematology-Oncology%20Clinics%20of%20North%20America,%20Volume%2026-5.jpg)
240 pages • missing pub info (editions)
ISBN/UID: 9781455749416
Format: Hardcover
Language: English
Publisher: Saunders
Publication date: 08 October 2012
Description
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies i...
Community Reviews
Content Warnings
![Non-CML Myeloproliferative Diseases, an Issue of Hematology/Oncology Clinics of North America, Volume 26-5 by Ross Levine](https://558130.bdp32.group/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEZhdmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f30f021a61a91e3f4a69d99c6d979065bb900798/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFJc0FXa0M5QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--038335c90cf75c275ae4d36968ac417dc4a0a3e3/Non-CML%20Myeloproliferative%20Diseases,%20an%20Issue%20of%20Hematology-Oncology%20Clinics%20of%20North%20America,%20Volume%2026-5.jpg)
240 pages • missing pub info (editions)
ISBN/UID: 9781455749416
Format: Hardcover
Language: English
Publisher: Saunders
Publication date: 08 October 2012
Description
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies i...